Top Page
Innovative Pharmaceutical Biotech
(0399)
Innovative Pharmaceutical Biotech (0399) vs. iShares MSCI Hong Kong ETF (EWH)
Innovative Pharmaceutical Biotech Business Overview & Revenue Model
Innovative Pharmaceutical Biotech Financial Statement Overview
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.27M | 2.09M | 6.59M | 8.07M | 11.14M | 15.19M |
| Gross Profit | 328.00K | 188.00K | 840.00K | 858.00K | 1.05M | 1.41M |
| EBITDA | -15.72M | -310.25M | 317.75M | -18.82M | 228.51M | -18.81M |
| Net Income | -563.85M | -345.94M | 103.40M | -245.70M | 296.54M | -395.75M |
Balance Sheet | ||||||
| Total Assets | 1.11B | 1.09B | 1.38B | 1.38B | 1.39B | 1.40B |
| Cash, Cash Equivalents and Short-Term Investments | 18.07M | 3.70M | 3.08M | 1.33M | 4.08M | 8.99M |
| Total Debt | 1.09B | 1.00B | 1.01B | 1.19B | 941.84M | 991.48M |
| Total Liabilities | 1.19B | 1.06B | 1.06B | 1.24B | 999.73M | 1.04B |
| Stockholders Equity | -783.77M | -681.19M | -611.51M | -795.07M | -549.37M | -595.35M |
Cash Flow | ||||||
| Free Cash Flow | 2.52M | -10.55M | -8.28M | -17.64M | -12.34M | -25.01M |
| Operating Cash Flow | 2.52M | -10.55M | -8.28M | -17.64M | -12.34M | -25.01M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -1.00K | 13.00K |
| Financing Cash Flow | 15.15M | 11.19M | 10.32M | 14.92M | 7.30M | 10.57M |
Innovative Pharmaceutical Biotech Technical Analysis
Innovative Pharmaceutical Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$32.26B | 11.64 | 29.64% | 1.84% | 36.70% | 22.26% | |
62 Neutral | HK$696.65M | 6.41 | 4.03% | ― | -0.92% | -71.88% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
48 Neutral | HK$437.13M | -1.59 | ― | ― | ― | ― | |
48 Neutral | HK$640.01M | -20.98 | -10.08% | 1.72% | -3.49% | -1567.01% | |
43 Neutral | HK$15.77B | -12.50 | -6.34% | 5.00% | 2.79% | -170.67% | |
41 Neutral | HK$1.00B | 25.19 | -12.38% | ― | 39.29% | -71.82% |
Innovative Pharmaceutical Biotech Corporate Events
Starcoin Group Limited has signed a memorandum of understanding with Newbridge Acquisition Limited, a NASDAQ-listed special purpose acquisition company, to explore a potential de-SPAC transaction involving the group and its assets or businesses. The non-binding MOU, dated 27 February 2026, sets a 180-day window for due diligence and negotiation of definitive agreements, after which it will lapse unless extended by mutual consent.
Management views the prospective de-SPAC deal as a major strategic milestone that could give the group direct access to U.S. capital markets and broaden its fundraising options to support business development and expansion. The board also believes a successful transaction would endorse the group’s business model and growth strategy, help unlock intrinsic value for shareholders, and potentially strengthen its competitive position, while cautioning investors that the deal may or may not proceed.
The most recent analyst rating on (HK:0399) stock is a Hold with a HK$0.18 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.
Starcoin Group Limited has agreed with Extrawell Pharmaceutical Holdings Limited to extend the long stop date for fulfilling conditions under the fourth deed of amendment relating to its outstanding convertible bonds from 31 March 2026 to 30 June 2026, or a later mutually agreed date. All other terms of the amendment remain unchanged, suggesting the parties are committed to completing the revised bond arrangements despite needing more time for procedural or regulatory conditions.
The company has also delayed the expected despatch date of a shareholder circular that will detail the fourth deed of amendment and convene a special general meeting, pushing the deadline from on or before 28 February 2026 to on or before 29 May 2026. Starcoin has advised shareholders and potential investors to exercise caution when dealing in its securities, underscoring the uncertainty around the timing and outcome of the proposed bond amendments and associated approvals.
The most recent analyst rating on (HK:0399) stock is a Hold with a HK$0.18 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.
Starcoin Group Limited has signed a strategic cooperation framework agreement with China International Digital Finance Group Limited to develop a gold‑backed real‑world asset tokenization project. Under the arrangement, China Digital Finance, a Hong Kong company wholly owned by a state‑owned entity, will supply the underlying gold assets and work to secure the necessary local issuer license.
Starcoin will provide blockchain infrastructure, security, and technical support for digital asset registration, circulation and real‑time auditability, while also bringing in additional strategic partners. The deal is expected to open new revenue streams, diversify income via technology services and RWA‑related businesses, and strengthen Starcoin’s international positioning in digital finance and cross‑border settlement.
The most recent analyst rating on (HK:0399) stock is a Hold with a HK$0.05 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.
Starcoin Group Limited has disclosed that the Hong Kong stock exchange has determined the company failed to maintain a sufficient level of operations as required under listing rules, a finding previously upheld by the Listing Committee. The group, whose shares trade in Hong Kong, faces questions about its ongoing compliance and the sustainability of its current business scale.
In response, the company has formally requested that the Listing Review Committee re-examine the Listing Committee’s decision made under Rule 13.24. Starcoin has cautioned shareholders and potential investors that the outcome of this review is uncertain and urged them to exercise care in trading its securities while awaiting further announcements on the process.
The most recent analyst rating on (HK:0399) stock is a Sell with a HK$0.06 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.
Starcoin Group Limited has been notified by the Hong Kong Stock Exchange’s Listing Committee that it failed to maintain a sufficient level of operations and assets of adequate value to justify its continued listing, leading to a decision to uphold the suspension of trading in its shares. The committee cited the company’s limited operating scale, lack of revenue from its research and development activities, early-stage status of newer ventures such as health supplements and blockchain technology, and profit forecasts lacking strong evidence, alongside concerns over its heavy reliance on intangible assets, unresolved maturity extensions for significant convertible bonds and ongoing going-concern uncertainties, all of which raise significant questions about the viability and sustainability of the business for investors and other stakeholders.
The most recent analyst rating on (HK:0399) stock is a Sell with a HK$0.08 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.
Starcoin Group Limited has announced a change to its principal place of business and contact details in Hong Kong, effective 19 January 2026. The company has relocated its main Hong Kong office to the 21st Floor of the Henley Building at 5 Queen’s Road Central in Central, Hong Kong, and has updated its telephone contact while keeping its facsimile number unchanged, a procedural move that signals an administrative shift in its local operations but does not indicate any change in corporate strategy or business direction for shareholders and stakeholders.
The most recent analyst rating on (HK:0399) stock is a Sell with a HK$0.10 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.
Starcoin Group Limited has issued a quarterly update on its efforts to address an auditor’s disclaimer of opinion over its going concern status, outlining progress and setbacks in debt restructuring, capital raising and cost management. The company has agreed a conditional fourth deed of amendment with major bondholder Extrawell Pharmaceutical Holdings to restructure HK$715 million of convertible bonds plus accrued interest into a larger HK$1.0 billion principal, extend the maturity to 28 July 2030, sharply reduce the interest rate to 0.1% and lower the conversion price to HK$1.0 per share, subject to regulatory and shareholder approvals. A planned equity subscription of 90 million new shares to raise roughly HK$27.78 million lapsed in November 2025 after conditions precedent were not met, leaving the group still searching for new funding via potential equity and debt options. Management is also pursuing stringent cost-control and efficiency measures to improve profitability and operating cash flow, steps that are critical to alleviating liquidity pressures and restoring investor confidence in the company’s long-term viability.
Starcoin Group Limited has signed a five-year Sponsored Research and Strategic Advisory Agreement with the Scaling Lab at Johns Hopkins University School of Medicine to deepen their collaboration on cardiometabolic and diabetes-related research. Under the deal, the lab will conduct non-clinical research into cardiovascular and cardiometabolic diseases, including diabetes and non-injectable diabetes treatment pathways, while Dr. Hunter Young’s team will advise the group on oral diabetes drugs, oral peptide therapeutics and drug-delivery systems, with Johns Hopkins retaining intellectual property ownership but granting Starcoin preferential licensing rights. The arrangement underpins Starcoin’s strategy to enhance the scientific quality and commercial prospects of its flagship oral insulin program and broader R&D business, aligning the company with a globally recognised medical research institution and potentially strengthening its long-term competitive position in diabetes treatment.